Oculogica’s patent allows expansion of its technology to a new indication.
December 21, 2021
NEW YORK, Dec. 21, 2020 — Oculogica, the leader in non-invasive assessment of concussion, announces today the granting of U.S. Patent No. 10,863,902 by the U.S. Patent and Trademark Office. This patent protects Oculogica’s method and system for assessing glaucoma in a patient using a noninvasive eye tracking system. The method and system also utilize a computer that compares pressures of the patient and determines the risk of glaucoma. This is Oculogica’s 6th patent in the U.S.
“With this new patent, Oculogica has the opportunity to develop a product to assess risk for normo-tensive glaucoma. We believe the potential impact of this is significant, given this is a type of glaucoma diagnosis that can be delayed using current screening methods. This patent also broadens the potential of our portfolio, leveraging our platform, approach and technology,” said Oculogica CEO, Rosina Samadani, Ph.D.
“The ease of the test, and the additional information it provides about a patient’s condition, could prove to be extremely helpful with early diagnosis of glaucoma,” said Dr. Thomas Castillo, ophthalmologist in Beaver Dam, WI, and co-author on the patent.
Oculogica currently holds five other patents in the U.S. This intellectual property portfolio has enabled them to be the first, and still only, aid in diagnosis of concussion authorized by the FDA that does not require a pre-injury test. They received this FDA clearance in December 2018. They also hold patents for elevated intracranial pressure and biometric identification of patients. This new patent for glaucoma contributes to the continued growth of the company, building on the recent announcement of the closing of an $8 Million Series A funding round, led by Titletown Tech, a venture capital fund and innovation center formed out of a partnership between the Green Bay Packers and Microsoft.
Oculogica Inc. is an eye tracking-based, neuro-diagnostic company founded by Dr. Uzma Samadani, a neurosurgeon at Centracare and the Minneapolis VA Medical Center, and Associate Professor of Bioinformatics and Computational Biology at the University of Minnesota School of Engineering. The company has developed the EyeBOX®, the first and only FDA cleared baseline-free, aid in diagnosis of concussion to help physicians objectively evaluate patients with suspected concussions. EyeBOX is a 4-minute test appropriate for ages 5 to 67. EyeBOX is used by leading healthcare organizations, including Midwest Orthopedics at Rush University and the clinics of the physician President of the California Brain Injury Association. To learn more about the company and the EyeBOX, visit www.oculogica.com.